DRUG NAME MECHANISM OF ACTION INDICATION / ADVERSE EFFECT NURSING RESPONSIBILITIES

CONTRAINDICATION

GENERIC: Suspension of inactivated and INDICATIONs: Body(Whole):Mild local Assessment & Drug
Hepatitis B purified hepatitis B surface To promote active immunity in tenderness at injection site, Effects
Vaccine[RECOMBINANT] antigen (HBsAg) derived from individuals at high risk of local inflammatory reaction  Note:The ACIP
BRAND: human plasma of screened potential exposure to hepatitis (swelling, heat, redness, recommends serologic
Engerix-B, asymptomatic HBsAg-positive B virus or HBsAg-positive induration, pain); fever, confirmation of
Recombivax HB carriers of hepatitis B virus. materials. Has been used malaise, fatigue, headache, postvaccination
CLASS: Hepatitis B vaccine simultaneously (into different dizziness, faintness, leg immunity in patients
antiinfective; vaccine recombinant is the first sites) with hepatitis B immune cramps, myalgia, arthralgia. undergoing dialysis
THERAPEUTIC vaccine produced by gene globulin (H-BIG) for post- and in
The recommended 3-dose splicing. No human plasma is exposure prophylaxis in GI:Nausea,vomiting, diarrhea. immunodeficient
regimen produces active used in its production. selected patients and in patients.
immunity against hepatitis B SOURCE: Saunders Drug infants born to HBsAg-positive Skin:Rash,urticaria, pruritus.  Monitor
infection by inducing Handbook mothers. temperature.Some
protective antibody (anti-HBs) RECOMBIVAX HB is indicated interaction drug:No clinically patients develop a
formation. for prevention of infection significant interactions temperature elevation
caused by all known subtypes established. of 38.3° C (101° F)
PHARMACOLOGIC: of hepatitis B virus. following vaccination
anti-HBs RECOMBIVAX HB is approved that may last 1 or 2 d.
DOSAGE: for use in individuals of all Patient & Family
Recombivax 0.5 mL (5 mcg) ages. Education
at 0, 1, and 6 mo; Engerix-B  Learn potential
0.5 mL (10 mcg) at 0, 1, and adverse reaction.
6 mo or 0, 1, 2, and 12 mo  Do not breast feed
ROUTE: while taking this drug
INTRAMUSCULAR without consulting
physician.
CONTRAINDICATION:
Hypersensitivity; concurrent
use of MAO-like drugs
(linezolid or methylene blue);
concurrent use of pimozide;
oral concentrate contains
alcohol; avoid patients with
known intolerance.
 DRUG NAME MECHANISM OF ACTION INDICATION / ADVERSE EFFECT NURSING RESPONSIBILITIES
CONTRAINDICATION

GENERIC: hytonadione is used in INDICATIONs: Pain and edema may occur  Document the giving
Vitamin K(Pytonadione) prophylaxis and treatment of Vitamin K is needed for at injection site. Allergic of the medication to
BRAND: hemorrhagic disease of the blood clotting. Newborn reaction such as rash and newborn to prevent
Aqua-Mephyton newborn. It promotes liver babies are given vitamin K urticaria,may also occur. an accidental
CLASS: formation of the clotting injections to prevent a doubling of the dose.
fat-soluble vitamins, factors II, VII, IX and X. At serious disease called Drug Interaction:  Observe for bleeding
THERAPEUTIC birth, the newborn does not haemorrhagic disease of the  anisindione (usually occurs on
Blood Coagulation have bacteria in the colon newborn (HDN).  cholestyramine second or third day).
PHARMACOLOGIC: that necessary for CONTRAINDICATION:  colesevelam Bleeding may be seen
Antifibrinolytic Agents synthesizing fat-soluble  hepatobiliary  colestipol as generalized
vitamin K.Therefore,the dysfunction  dicumarol ecchymoses or
DOSAGE: newborn may have  mineral oil bleeding from
Recombivax 0.5 mL (5 mcg) deceased levels of  orlistat umbilical cord,
at 0, 1, and 6 mo; Engerix-B prothrombin during the first 5  sevelamer circumcision site, nose
0.5 mL (10 mcg) at 0, 1, and to 8 days of life reflected by  warfarin or gastrointestinal
6 mo or 0, 1, 2, and 12 mo a prolongation of tract.
ROUTE: prothrombin time.SOURCE:  Observe for jaundice
INTRAMUSCULAR Saunders Drug Handbook and
kernicterus,especially
in preterm infants.
 Observe for signs of
local inflammation.
 Apply pressure to the
injection site to
prevent further
bleeding
 Protect drug from
light.
 Give vitamin K before
circumcision
procedure
 DRUG NAME MECHANISM OF ACTION INDICATION / ADVERSE EFFECT NURSING
CONTRAINDICATION RESPONSIBILITIES

GENERIC: BCG vaccine is an INDICATIONs: CNS: Intravesical administration: malaise, Assessment & Drug
BCG (bacille immunization agent for To protect tuberculin skin dizziness, headache, Effects
Calmette-Guerin) tuberculosis (TB). It is an test-negative infants and weakness. Endocrine: Hyperpyrexia.
BRAND: attenuated strain of the children, and groups with  Monitor for S&S
Tice BCG Live (for bacillus Calmette and an excessive rate of new GI: Abdominal pain, anorexia, constipation, of systemic BCG
intravesical use), Tice Guérin strain TB infections; carcinoma in nausea, vomiting, diarrhea; hepatic infection: Fever,
BCG Vaccine, Theracys of Mycobacterium bovis. situ of the bladder. dysfunction following intratumor injection,
chills, severe
3, TheraCys, BCG BCG vaccine stimulates CONTRAINDICATION: granulomatous hepatitis.
malaise, or cough.
Vaccine (obsolete) the reticuloendothelial Impaired immune
 Culture blood and
CLASS: system (RES) to produce responses, Urogenital: Intravesical administration: bladder
VACCINE; macrophages that do immunosuppressive spasms, clot retention, decreased bladder urine, if systemic
ANTINEOPLASTIC; not allow mycobacteria corticosteroid therapy, capacity, decreased urine flow, dysuria, infection is
IMMUNOMODULATOR; to multiply. BCG live is asymptomatic carriers hematuria, incontinence, nocturia, UTI, cystitis, suspected.
BIOLOGICAL RESPONSE used intravesically as a with positive HIV serology; hemorrhagic cystitis, penile pain, prostatism.  Assess for regional
MODIFIER biological response fever; UTI; lactation. lymph node
modifier for bladder Hematologic: Thrombocytopenia, enlargement and
THERAPEUTIC: cancer in situ. BCG live is eosinophilia, anemia, leukopenia, disseminated report fistula
BCG is active thought to cause a local, intravascular coagulation. formation.
immunotherapy, which chronic inflammatory
stimulates the immune response involving Respiratory: Cough (rare), pulmonary Patient & Family
mechanism to reject the macrophage and granulomas, pulmonary infection.
Education
tumor. It enhances the leukocyte infiltration of
cytotoxicity of the bladder. This local Skin: Abscess with recurrent discharge, red
 Review potential
macrophages. inflammatory response papule that scales or ulcerates in about 5–6
leads to destruction of wk, dermatomyositis, granulomas at injection adverse effects.
PHARMACOLOGIC:
superficial tumor cells. site 4–6 wk after inoculation, keloid formation,  Keep vaccination
Antifibrinolytic Agents
SOURCE: Saunders Drug lupus vulgaris. site clean until
DOSAGE: Handbook local reaction has
Recombivax 0.5 mL (5 subsided.
mcg) at 0, 1, and 6 mo; Body as a Whole: Systemic BCG  Do not breast feed
Engerix-B 0.5 mL (10 infection, chills, flu-like until cleared to do
mcg) at 0, 1, and 6 mo or syndrome, anaphylaxis (rare), allergic so by physician.
0, 1, 2, and 12 mo reactions, lymphadenitis.
ROUTE:
INTRADERMAL
Drug Interaction:
 abemaciclib
 acalabrutinib
 adalimumab
 aldesleukin
 alefacept
 altretamine
 amikacin
 amikacin liposome
 aminosalicylic acid
 amoxicillin
 ampicillin
 anakinra
 anti-thymocyte globulin (rabbit)
 asparaginase escherichia coli
 axicabtagene ciloleucel
 azacitidine